Taipei, Taiwan, 16 May 2017 – ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has successfully conducted an initial public offering of common shares via competitive auction. ASLAN offered 10,409,000 shares by auction. A total of 638 bids were received, of which 604 bids were eligible. The winning bids were decided by American auction format. The results are of the auction are shown below:
Lowest winning bid: NT$64
Highest winning bid: NT$166
Weighted average winning bid: NT$68.92
In accordance with the pre-IPO allocation, 2,602,000 shares will be made available via public subscription with the offer price of NT$68.92. Applications will begin on 18 May 2017 and end on 22 May 2017. ASLAN Pharmaceuticals will list on the Taipei Exchange (TPEx) on 1 June 2017.
ASLAN currently has a pipeline of five novel compounds and one modybodies platform, focusing on the treatment of Asia-prevalent tumours. Its lead asset, varlitinib, has commenced a global pivotal study in biliary tract cancer following the Investigational New Drug approval from the US Food & Drug Administration. Led by a team of highly-experienced industry veterans with a strong track record in clinical development, ASLAN has been able to generate revenues through two outlicensing deals, attract international institutional investors, and forge strong partnerships with world-leading research institutions and international biopharmaceutical companies.
Ends
Media Contacts
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333
E-mail: media@aslanpharma.com
Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com